Not a traditional drug phase: Mitoquinone for Long-COVID
The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress and inflammation associated with aging and further induced by COVID-19. The investigators expected outcomes will have an important positive impact because they will provide scientifically sound recommendations for rehabilitation to improve vascular endothelial function and minimize the long-term consequences of COVID-19.
Official registry: https://clinicaltrials.gov/study/NCT05373043 · VA Office of Research and Development · enrollment listed as 300
What this phase means
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Mitoquinone, or Placebo. The registry lists allocation as randomized. The proposed focuses on improving both morbidity and mortality in older Veterans and those recovering from COVID-19 by developing rehabilitation therapies to augment vascular endothelial function by combating the oxidative stress and inflammation associated with aging and further induced by COVID-19.
They plan to enroll about 300 people at Salt Lake City. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Evaluating the Long-term Health Consequences of COVID-19 and Rehabilitation Therapies to Speed Convalescence
Interventions: Mitoquinone, Placebo
Primary outcome (registry wording): Change in Flow Mediated Dilation (FMD)
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Long-COVID and COVID-recovered patients must have SARS-CoV-19 positive test near the time of COVID-19 diagnosis
- Long-COVID and COVID-recovered patients must be 3-12 months post-initial COVID-19 diagnosis
Who the registry excludes
- Orthopedic limitations that would prohibit exercise
- Current smokers and individuals that stopped smoking in the last 10 years
- Already taking Mito-Q or unwilling to cease dietary supplements for participation
- Any other condition or event considered exclusionary by the PIs or a physician
Public study contact (from the registry)
Joel D Trinity, PhD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- VA Salt Lake City Health Care System, Salt Lake City, UT — Salt Lake City, Utah (recruiting)
FAQ about this NCT record
Is NCT05373043 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT05373043?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT05373043?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary